Company intelligence / Profile preview

Proteotype Diagnostics

Cambridge, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

Proteotype’s Enlighten™ test is in clinical validation, awarded £1.5 million grant for a multi-cancer early detection assay based on measuring host response proteins; no published clinical results yet, but described as a novel and pioneering platform for earlier and broader cancer detection.

Therapeutic areas: OncologyOther
Modalities: ProteinLiquid biopsyDiagnostic assay
Industry: Protein Biomarker Diagnostics

Partnerships

University of Southampton (validation of Enlighten™ test)Five Alarm Bio (senescence biomarker research)

Beyond the preview

Go deeper on Proteotype Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteotype Diagnostics.

Explore the full profile